Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes.
about
Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies.Implementing genome-driven personalized cardiology in clinical practice.Precision medicine for cardiovascular disease : Learning lessons from cardiomyopathies.Gene Editing and Gene-Based Therapeutics for Cardiomyopathies.S100A4 as a Target of the E3-Ligase Asb2β and Its Effect on Engineered Heart TissuePerspectives on current recommendations for genetic testing in HCM
P2860
Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Evaluation of MYBPC3 trans-Spl ...... n iPSC-Derived Cardiomyocytes.
@en
type
label
Evaluation of MYBPC3 trans-Spl ...... n iPSC-Derived Cardiomyocytes.
@en
prefLabel
Evaluation of MYBPC3 trans-Spl ...... n iPSC-Derived Cardiomyocytes.
@en
P2093
P2860
P1476
Evaluation of MYBPC3 trans-Spl ...... n iPSC-Derived Cardiomyocytes.
@en
P2093
Arne Hansen
Aya Shibamiya
Charles Redwood
Elisabeth Krämer
Frederik Flenner
Giulia Mearini
Julia Münch
Lucie Carrier
Monica Patten
P2860
P304
P356
10.1016/J.OMTN.2017.05.008
P577
2017-05-17T00:00:00Z